Related Experiment Videos
Clinical grading in chronic graft-versus-host disease: is it time for change?
1Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21231-1000, USA. gakpek@jhmi.edu
Insights
Chronic graft-versus-host disease (cGVHD) significantly impacts outcomes after allogeneic stem cell transplants. New prognostic factors like skin involvement, thrombocytopenia, and onset type are identified to improve patient stratification and treatment strategies.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Allogeneic hematopoietic stem cell transplantation (allo-SCT) offers cures for hematologic malignancies.
- Chronic graft-versus-host disease (cGVHD) is a major complication affecting long-term outcomes and quality of life post-allo-SCT.
- Increasing use of blood stem cells and donor lymphocyte infusions (DLI) are associated with rising cGVHD incidence, often refractory to treatment.
Purpose of the Study:
- To develop a more accurate prognostic model for chronic graft-versus-host disease (cGVHD) after allo-SCT.
- To identify key risk factors that predict survival outcomes in cGVHD patients.
- To establish a foundation for a new clinical grading system that stratifies patients by prognosis.
Main Methods:
- Multivariate analysis was employed to identify independent risk factors for survival without recurrent malignancy.
- Three specific factors were identified: extensive skin involvement (>50% BSA), thrombocytopenia, and progressive-type onset of cGVHD.
- The prognostic model is currently undergoing validation in independent patient cohorts from multiple institutions.
Main Results:
- Three independent risk factors significantly impacting survival without recurrent malignancy were identified.
- These factors include extensive skin involvement, thrombocytopenia, and a progressive onset of cGVHD.
- The identified factors are being validated to ensure the robustness of the prognostic model.
Conclusions:
- The current cGVHD grading system has limited utility in predicting patient outcomes.
- A new prognostic model incorporating extensive skin involvement, thrombocytopenia, and progressive onset is being developed.
- This model is expected to enable better patient stratification, clinical trial design, and management of cGVHD, particularly within the 'extensive stage' category.
Abstract:
Many hematologic disorders, leukemias and lymphomas in particular, can be cured with allogeneic hematopoietic stem cell transplantation (allo-SCT). However, chronic graft-versus-host disease (cGVHD) appears to remain as a major determinant of long term outcome and quality of life following allo-SCT. The gradual increase in the incidence of cGVHD over the past decade has recently gained another momentum along with the use of blood as a source of stem cells. Donor lymphocyte infusion (DLI) is also associated with a progressive form of cGVHD, mostly refractory to treatment. Prediction of the outcome of patients with newly diagnosed chronic GVHD may be important in identifying those who are likely to benefit from reduced treatment and patients who are unlikely to have a sustained response to standard treatment. In addition, a reliable predictive model could allow us to design better clinical trials and facilitate the communication among the centers. Although it is highly reproducible, the current system of grading in cGVHD is of limited utility since it does not stratify patients for outcome. It divides patients into those needing treatment (extensive cGVHD) and those who do not (limited cGVHD). Therefore, a new clinical grading system is needed to classify all patients based on their prognosis so like patients with similar features can be grouped for study and clinical management purposes. Using multivariate analysis, we recently identified three independent risk factors affecting the survival without recurrent malignancy. These factors are extensive skin involvement (>50% BSA), thrombocytopenia, and progressive-type onset of cGVHD. We are in the process of validating this prognostic model in three other cohorts from different institutions. We expect that the new grading system, based on this model, may allow us to identify the diversity of outcome within "extensive stage" cGVHD.